➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Boehringer Ingelheim
Baxter
Express Scripts
Mallinckrodt

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 8,247,421

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,247,421
Title:5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Inventor(s): Mortimore; Michael (Oxfordshire, GB), Young; Stephen Clinton (Oxfordshire, GB), Everitt; Simon Robert Lorrie (Oxfordshire, GB), Knegtel; Ronald (Oxfordshire, GB), Pinder; Joanne Louise (Oxfordshire, GB), Rutherford; Alistair Peter (Oxfordshire, GB), Durrant; Steven (Oxfordshire, GB), Brenchley; Guy (Oxfordshire, GB), Charrier; Jean-Damien (Oxfordshire, GB), O\'Donnell; Michael (Oxfordshire, GB)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:12/448,489
Patent Claims:see list of patent claims

Details for Patent 8,247,421

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Vertex Pharmaceuticals Incorporated (Cambridge, MA) 2039-02-26 RX search
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Vertex Pharmaceuticals Incorporated (Cambridge, MA) 2039-02-26 RX search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial Vertex Pharmaceuticals Incorporated (Cambridge, MA) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Vertex Pharmaceuticals Incorporated (Cambridge, MA) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Vertex Pharmaceuticals Incorporated (Cambridge, MA) 2039-02-26 RX search
Eisai Inc ONTAK denileukin diftitox VIAL 103767 001 1999-02-05   Start Trial Vertex Pharmaceuticals Incorporated (Cambridge, MA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
Baxter
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.